Presenting at a prestigious conference like the ARVO Annual Meeting can significantly enhance a company's reputation in its industry. For Ocugen, this opportunity to showcase its Modifier Gene Therapy Platform could attract positive attention from investors, researchers, and potential partners, potentially leading to a short-term positive impact on its stock price. The relevance is high as the news directly involves Ocugen's core research activities, and the importance is marked at 80 considering the potential for increased visibility and credibility in the biotech sector. The confidence level is set at 75, acknowledging the general positive trend for companies demonstrating innovation and progress in their field, though market conditions and other external factors could influence the actual impact.